高级检索

P-糖蛋白辅助治疗子宫内膜癌的近远期效果观察

Observation on short- and long-term effects of P-glycoproteinin the adjuvant treatment of endometrial cancer

    摘要
  • 摘要:
      目的  探讨P-糖蛋白抑制剂对子宫内膜癌的辅助治疗效果。
      方法  随机选取本院收治的80例子宫内膜癌患者为研究对象, 根据治疗方式不同分为对照组和观察组。对照组用常规化疗治疗，观察组加用P-糖蛋白辅助治疗，对2组治疗效果进行比较。
      结果  观察组疾病治疗总有效率、不良反应发生率分别为62.50%、7.50%, 与对照组的32.50%、25.00%相比，差异有统计学意义(P < 0.05); 2组患者治疗前生命质量、肿瘤抗原125(CA125)、癌胚抗原(CEA)、糖链抗原19-9(CA19-9)、甲壳质酶蛋白(YKL-40)和人附睾蛋白(HE4)水平差异无统计学意义(P>0.05); 观察组治疗后生命质量显著高于对照组，血清肿瘤标志物、YKL-40和HE4水平显著低于对照组(P < 0.05)。
      结论  P-糖蛋白辅助治疗子宫内膜癌效果显著，安全性高。

     

    Abstract:
      Objective  To investigate the adjuvant effect of P-glycoprotein inhibitor on endometrial cancer.
      Methods  A total of 80 patients with endometrial cancer admitted to our hospital were randomly selected as research objects, and were divided into control group and observation group. The control group was treated with conventional chemotherapy, and the observation group was added P-glycoprotein adjuvant therapy. The therapeutic effects of the two groups were compared.
      Results  The total effective rate of disease treatment, and the incidence of adverse reactions in the observation group were 62.50%, 7.50%, respectively, and were 32.50% and 25.00% in the control group, a significant difference were observed in two groups (P < 0.05). Before treatment, quality of life, carbohydrate antigen 125(CA125), carcino-embryonic antigen(CEA), carbohydrate antigen 19-9 (CA19-9), chitosan ester enzyme protein (YKL-40) and human epididymis protein (HE4) level of two groups showed no statistically difference (P>0.05), and the quality of life after treatment in the observation group was obviously higher than that of control group, serum tumor markers, YKL-40 and HE4 levels were significantly lower than that in the control group(P < 0.05).
      Conclusion  P-glycoprotein is a treatment with high efficacy and safety in the treatment of endometrial cancer.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回